- Home
- YQ vs ADAP Comparison
YQ vs ADAP Comparison
Compare YQ & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- ADAP
- Stock Information
- Founded
- YQ 2012
- ADAP 2008
- Country
- YQ China
- ADAP United Kingdom
- Employees
- YQ N/A
- ADAP N/A
- Industry
- YQ Other Consumer Services
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- ADAP Health Care
- Exchange
- YQ Nasdaq
- ADAP Nasdaq
- Market Cap
- YQ 19.4M
- ADAP 21.3M
- IPO Year
- YQ 2020
- ADAP 2015
- Fundamental
- Price
- YQ $2.65
- ADAP $0.06
- Analyst Decision
- YQ
- ADAP Hold
- Analyst Count
- YQ 0
- ADAP 6
- Target Price
- YQ N/A
- ADAP $1.02
- AVG Volume (30 Days)
- YQ 21.4K
- ADAP 62.3M
- Earning Date
- YQ 09-03-2025
- ADAP 11-12-2025
- Dividend Yield
- YQ N/A
- ADAP N/A
- EPS Growth
- YQ N/A
- ADAP N/A
- EPS
- YQ N/A
- ADAP N/A
- Revenue
- YQ $20,003,071.00
- ADAP $65,084,999.00
- Revenue This Year
- YQ N/A
- ADAP N/A
- Revenue Next Year
- YQ N/A
- ADAP $52.35
- P/E Ratio
- YQ N/A
- ADAP N/A
- Revenue Growth
- YQ N/A
- ADAP N/A
- 52 Week Low
- YQ $1.26
- ADAP $0.04
- 52 Week High
- YQ $3.19
- ADAP $1.17
- Technical
- Relative Strength Index (RSI)
- YQ 70.01
- ADAP 38.42
- Support Level
- YQ $2.10
- ADAP $0.06
- Resistance Level
- YQ $2.81
- ADAP $0.07
- Average True Range (ATR)
- YQ 0.16
- ADAP 0.01
- MACD
- YQ 0.08
- ADAP 0.01
- Stochastic Oscillator
- YQ 82.34
- ADAP 53.33
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.